Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ibuzatrelvir in Renal Impairment
NCT06586216Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ibuzatrelvir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration, Area under the Plasma Concentration-time Profile from Time Zero to Extrapolated Infinite Time and 1 more. Started Sep 2024; status: completed.
02
Drugs
ibuzatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06586216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586216.